Long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis.

IF 1.1 4区医学 Q3 UROLOGY & NEPHROLOGY

Clinical nephrology Pub Date : 2023-08-01 DOI:10.5414/CN111012

Shohei Fukunaga, Masahiro Egawa, Manabu Shiono, Takafumi Ito, Kazuaki Tanabe

{"title":"Long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis.","authors":"Shohei Fukunaga, Masahiro Egawa, Manabu Shiono, Takafumi Ito, Kazuaki Tanabe","doi":"10.5414/CN111012","DOIUrl":null,"url":null,"abstract":"Aim: In this study, we aimed to investigate the long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis.Materials and methods: Patients on maintenance hemodialysis at our institution who switched from oral to intravenous calcimimetics between March 1, 2017 and October 31, 2018 were enrolled. We compared tablet number; chronic kidney disease-mineral and bone disorder (CKD-MBD)-related drug cost; and serum corrected calcium, serum phosphorous, and serum intact parathyroid hormone levels before and 1, 2, and 3 years after switching from oral to intravenous calcimimetics.Results: There were 15 patients (11 males and 4 females; mean age 60.9 ± 9.2 years). The tablet numbers and CKD-MBD-related drug cost before and 3 years after switching to calcimimetics were 12.1 ± 8.1 tablets/day vs. 8.4 ± 5.0 tablets/day (p = 0.0371) and 9,654.5 ± 6,206.8 yen (87.8 ± 56.4 U.S. dollars)/week vs. 7,231.7 ± 3,490.9 yen (65.7 ± 31.7 U.S. dollars)/week (p = 0.0406), respectively.Conclusion: Switching from oral to intravenous calcimimetics decreased intact parathyroid hormone levels and reduced the tablet numbers and CKD-MBD-related drug cost for a long period without significant adverse effects.","PeriodicalId":10396,"journal":{"name":"Clinical nephrology","volume":"100 2","pages":"60-66"},"PeriodicalIF":1.1000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CN111012","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: In this study, we aimed to investigate the long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis.

Materials and methods: Patients on maintenance hemodialysis at our institution who switched from oral to intravenous calcimimetics between March 1, 2017 and October 31, 2018 were enrolled. We compared tablet number; chronic kidney disease-mineral and bone disorder (CKD-MBD)-related drug cost; and serum corrected calcium, serum phosphorous, and serum intact parathyroid hormone levels before and 1, 2, and 3 years after switching from oral to intravenous calcimimetics.

Results: There were 15 patients (11 males and 4 females; mean age 60.9 ± 9.2 years). The tablet numbers and CKD-MBD-related drug cost before and 3 years after switching to calcimimetics were 12.1 ± 8.1 tablets/day vs. 8.4 ± 5.0 tablets/day (p = 0.0371) and 9,654.5 ± 6,206.8 yen (87.8 ± 56.4 U.S. dollars)/week vs. 7,231.7 ± 3,490.9 yen (65.7 ± 31.7 U.S. dollars)/week (p = 0.0406), respectively.

Conclusion: Switching from oral to intravenous calcimimetics decreased intact parathyroid hormone levels and reduced the tablet numbers and CKD-MBD-related drug cost for a long period without significant adverse effects.

查看原文本刊更多论文

血液透析患者从口服改为静脉溶钙剂的长期益处。

目的:在这项研究中，我们旨在调查血液透析患者从口服改为静脉注射钙化剂的长期益处。材料和方法:纳入2017年3月1日至2018年10月31日期间在我院进行维持性血液透析的患者，这些患者从口服钙化剂转为静脉钙化剂。我们比较片剂数量;慢性肾脏疾病-矿物质和骨骼疾病(CKD-MBD)相关药物成本;血清钙，血清磷，血清完整甲状旁腺激素水平在从口服到静脉化钙剂转换前，1年，2年和3年后。结果:15例患者(男11例，女4例;平均年龄60.9±9.2岁)。改用钙化剂治疗前和3年后ckd - mbd相关药物费用分别为12.1±8.1片/天和8.4±5.0片/天(p = 0.0371)， 9,654.5±6,206.8日元(87.8±56.4美元)/周和7,231.7±3,490.9日元(65.7±31.7美元)/周(p = 0.0406)。结论:口服钙化剂转为静脉注射钙化剂可降低完整甲状旁腺激素水平，长期降低ckd - mbd相关药物的片剂数量和成本，且无明显不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical nephrology 医学-泌尿学与肾脏学

CiteScore

2.10

自引率

9.10%

发文量

138

审稿时长

4-8 weeks

期刊介绍： Clinical Nephrology appears monthly and publishes manuscripts containing original material with emphasis on the following topics: prophylaxis, pathophysiology, immunology, diagnosis, therapy, experimental approaches and dialysis and transplantation.